Skip to content

Galectin and Respiratory Weaning

Prognostic Value of Galectin-3 for Success of Respiratory Weaning

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05054556
Acronym
Gal-3
Enrollment
150
Registered
2021-09-23
Start date
2021-11-01
Completion date
2025-06-30
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Galectin-3 During Respiratory Weaning

Brief summary

Galectin-3 is a biomarker for fibrotic activity. In the course of invasive ventilation, fibrotic changes in the lungs may occur. The study aims to investigate whether the level of galectin-3 levels correlates with clinical weaning parameters.

Detailed description

Galectin-3 (Gal-3) is a protein with an important role in cell-cell adhesion, cell-matrix interactions, macrophage activation, angiogenesis, metastasis and apoptosis. Galectin-3 is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space.It is involved in different biological processes: cell adhesion, cell activation and chemoattraction, cell growth and differentiation, cell cycle, and apoptosis. Several studies revealed the function of galectin-3 in cancer, inflammation and (lung) fibrosis, heart disease, and stroke. Expression of galectin-3 is associated with heart failure, including myofibroblast proliferation, fibrogenesis, tissue repair, inflammation, and ventricular remodeling. A correlation between galectin-3 expression levels and various types of fibrosis has been found. Galectin-3 is upregulated in idiopathic pulmonary fibrosis. Mechanical ventilation can cause lung damage, or worsen it if already present. This phenomenon is called ventilation-induced lung damage. Main mechanisms are high tidal volumes causing overexpansion of the lungs (volutrauma), high airway pressure (barotrauma) and cyclical collapse and reopening of atelectatic alveolar regions (atelectrauma) leading to a pulmonary inflammatory reaction called bio-trauma. To evaluate the (potential) lung injury serum levels of galectin-3 are measured on admission to our hospital. During respiratory weaning invasiveness of ventilation will be reduced. Data relating biomarkers especially galectin3 during/after successful respiratory weaning are missing. This is why follow up measurements of galectin-3 will be done and correlated with ventilation parameters/duration/ success of respiratory weaning. Prior studies evaluated the role of proGRP and CA 15-3 in patients with lung fibrosis. As a part of the study galectin-3 serum levels will be correlated with serum levels of proGRP and CA 15-3. In summary the aim of this study is to evaluate the diagnostic value of galectin-3 in respiratory weaning.

Interventions

DIAGNOSTIC_TESTLabaratory tests

Estimation of serum levels of the following parameters: galectin-3, proBNP, TNI, proGRP, CA15-3, CK, creatinine, urea, crp, pct, leucozytes

Sponsors

Asklepios Schlossberg Clinic Bad Koenig
CollaboratorUNKNOWN
Asklepios Neurological Clinic Bad Salzhausen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* written informed consent * mechanical ventilation

Exclusion criteria

* history of pulmonary disease * left ventricular ejection fraction\<45% * missing declaration of consent

Design outcomes

Primary

MeasureTime frameDescription
To correlate the serum levels of galectin-3 and duration of respiratory weaning.2-3 monthsLabaratory test+Clinical data.

Secondary

MeasureTime frameDescription
Serum levels of galectin-3 on admission, after weaning and discharge from hospital. Correlation of: galectin-3 and duration of respiratory weaning invasiveness of ventilation parameters and galectin-3 serum levels of galectin-3, proGRP and CA 15-3.2-3 monthsClinical data, labaratory tests.

Countries

Germany

Contacts

Primary ContactDirk Bandorski, MD
d.bandorski@asklepios.com+496043804212

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026